Many clinical studies rely on site-based patient-reported outcome measures (PROMs), but the sudden requirement for social distancing and other restrictions because of the recent COVID-19 crisis necessitated adaptations to data collection strategies.
Learn from eCOA and ePRO expert, Dr. Bill Byrom, how mixing modes of PRO data collection allows sponsors to continue conducting clinical trials during the pandemic. He also details why sponsors and sites need to consider the following:
- Existing equivalence data
- Identifying data captured by alternative methods
- Maintaining data integrity
